Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Tax Provisions: 2014-2025

Historic Tax Provisions for Zevra Therapeutics (ZVRA) over the last 9 years, with Sep 2025 value amounting to -$433,000.

  • Zevra Therapeutics' Tax Provisions was N/A to -$433,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year change of. This contributed to the annual value of $15.4 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Zevra Therapeutics' Tax Provisions stood at -$433,000, which was down 119.69% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Tax Provisions registered a high of $15.4 million during Q4 2024, and its lowest value of -$786,000 during Q4 2022.
  • Its 3-year average for Tax Provisions is $2.0 million, with a median of $70,000 in 2024.
  • In the last 5 years, Zevra Therapeutics' Tax Provisions tumbled by 2,475.00% in 2023 and then skyrocketed by 3,041.43% in 2025.
  • Quarterly analysis of 5 years shows Zevra Therapeutics' Tax Provisions stood at $34,000 in 2021, then tumbled by 2,411.76% to -$786,000 in 2022, then skyrocketed by 636.36% to $177,000 in 2023, then skyrocketed by 194.59% to $15.4 million in 2024, then surged by 3,041.43% to -$433,000 in 2025.
  • Its Tax Provisions stands at -$433,000 for Q3 2025, versus $2.2 million for Q2 2025 and $1.2 million for Q1 2025.